Abstract Details

Title Real-world Validation of the Electrode Identifier for Electrophysiology-guided DBS Programming

Topic Movement Disorders

Presentation(s) S11 - Movement Disorders: Technological Advances in Diagnostics and Therapeutics (4:18 PM-4:30 PM)

Poster/Presentation
Number 005

Objective Evaluate the effectiveness of stimulation contact selection based on EI compared to standard clinical DBS programming.

Background Deep brain stimulation (DBS) is an effective treatment for Parkinson’s disease (PD), Essential Tremor (ET), and dystonia. Optimizing DBS settings often requires lengthy trial-and-error programming sessions. Modern DBS systems allow for intracranial electrophysiological recordings, offering a potentially more objective method. A new technology, the BrainSense Electrode Identifier (EI), was introduced to automatically identify the electrode contact with the strongest relevant electrophysiological signal.

Design/Methods We conducted a retrospective review of DBS patients at the University of Florida. Inclusion criteria include: 1) Diagnosis of PD, ET or dystonia from a movement disorders neurologist, 2) Bilateral DBS implantation with a Medtronic Percept pulse generator and Medtronic Sensight B33005 or B33015 leads, 3) Completed at least 6 months of DBS programming. We compared the monopolar contact with the highest beta signal to the clinically optimized contact after 6 months.

Results We analyzed local field potential recordings from 37 DBS leads implanted in 21 patients: 12 with PD, 7 with ET, and 2 with dystonia. Leads were distributed across three targets: 6 in the subthalamic nucleus (STN), 21 in the Globus Pallidus Internus (GPi), and 10 in the thalamus. The EI-selected contact matched the clinically optimized contact in 56.5% of PD cases, 27.3% of ET cases, and 0% of dystonia cases. By target, matches occurred in 66.7% of STN leads, 42.9% of GPi leads, and 30% of thalamic leads.

Conclusions EI showed the highest accuracy in PD cases, especially in STN leads, where it matched clinical contacts in more than 65% of cases. While performance varied across targets, EI may be useful for rapid screening of electrophysiologic biomarkers. However, further research is needed to optimize its clinical utility across diverse patient populations and brain targets.

Authors/Disclosures
Brooke C. Dolan PRESENTER	Ms. Dolan has nothing to disclose.
Jackson Cagle	Jackson Cagle has nothing to disclose.
Coralie De Hemptinne, PhD	The institution of Mrs. De Hemptinne has received research support from Alpha Omega. Mrs. De Hemptinne has received personal compensation in the range of $0-$499 for serving as a grant review with Michael J Fox foundation.
Joshua Wong, MD (University of Florida College of Medicine - Neurology)	The institution of Dr. Wong has received research support from NIH.

��ɫ��

��ɫ��